SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-20-000033
Filing Date
2020-11-09
Accepted
2020-11-09 07:03:00
Documents
16
Period of Report
2020-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20201109.htm   iXBRL 8-K 43492
2 EX-99.1 zentalisq320208-kerex99.htm EX-99.1 68144
8 GRAPHIC image_01a.jpg GRAPHIC 5507
  Complete submission text file 0001725160-20-000033.txt   279496

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20201109.xsd EX-101.SCH 2423
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT zntl-20201109_cal.xml EX-101.CAL 710
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zntl-20201109_def.xml EX-101.DEF 1643
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20201109_lab.xml EX-101.LAB 25998
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20201109_pre.xml EX-101.PRE 13731
9 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20201109_htm.xml XML 11802
Mailing Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 201296046
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences